2016 CME: Do You Think Like the Experts? An Interactive Discussion of Clinical Scenarios in Ovarian Cancer

 

 Activity Overview

This CME-certified, interactive Webcast contains polling, video, and downloadable slides from the highly interactive symposium Do You Think Like the Experts? An Interactive Discussion of Clinical Scenarios in Ovarian Cancer, a prIME Oncology educational activity that was held on 23 January 2016 at the Progress and Controversies in Gynecologic Oncology Conference in Barcelona, Spain.

Topics

Welcome, introduction of faculty, and explanation of format
Bradley J. Monk, MD, FACS, FACOG
What’s compelling in the management of ovarian cancer in 2016?
Nicoletta Colombo, MD
Upfront therapy of advanced ovarian cancer
Antonio González Martín, MD
Platinum-sensitive relapse: Role of BRCA mutation status?
Philipp Harter, MD
Platinum-sensitive relapse: Role of antiangiogenic therapy and secondary cytoreduction?
Mansoor Mirza, MD
Platinum resistant/refractory relapse
Bradley J. Monk, MD, FACS, FACOG

Faculty

CHAIR

• Bradley J. Monk, MD, FACS, FACOGCreighton University School of Medicine at St. Joseph’s Hospital and Medical Center
  Phoenix, Arizona, United States

FACULTY

• Nicoletta Colombo, MDUniversity of Milan–Bicocca
  European Institute of Oncology
  Milan, Italy
• Philipp Harter, MDKliniken Essen-Mitte
  Essen, Germany
• Antonio González MartÍn, MDMD Anderson Cancer Center Madrid
  Madrid, Spain
• Mansoor R. Mirza, MDCopenhagen University Hospital
  Rigshospitalet
  Copenhagen, Denmark

Target Audience

This meeting is intended for gynecologists, oncologists, radiation therapists, surgeons, pathologists, and other practitioners including allied health professionals, involved in the diagnosis and management of gynecologic malignancies.

Learning Objectives

After successful completion of this educational activity, participants should be able to:

• Identify treatments that are consistent with best practices for the management of advanced ovarian cancer following debulking surgery, including antiangiogenic compounds and PARP inhibitors
• Evaluate the surgical and systemic options available for the management of platinum-sensitive relapsed ovarian cancer
• Discuss the current and emerging treatment options for platinum-resistant ovarian cancer